ADIPOR1 and renal cell carcinoma: Since our data suggest that increased expression of ERp46 promotes RCC growth in vivo and we have previously shown that adiponectin suppresses RCC progression through the interaction with its receptor AdipoR1 [7], ERp46 seems an appealing potential therapeutic target in RCC.